Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

BACKGROUND: Checkpoint inhibitors revolutionized the treatment of metastatic melanoma patients. Although tumor burden and lactate dehydrogenase (LDH) are associated with overall survival (OS), the impact of tumor growth kinetics remains elusive and in part contradictory. The aims of this study were...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Nikolaus B, Lenders, Max M, Kühl, Kathrin, Reinhardt, Lydia, André, Fiona, Dudda, Milena, Ring, Natalie, Ebel, Chiara, Stäger, Ramon, Zellweger, Caroline, Lang, Roland, Paar, Michael, Gussek, Philipp, Richtig, Georg, Stürmer, Suzan H, Kimeswenger, Susanne, Oellinger, Angela, Forschner, Andrea, Leiter, Ulrike, Weide, Benjamin, Gassenmaier, Maximilian, Schraag, Amadeus, Klumpp, Bernhard, Hoetzenecker, Wolfram, Berking, Carola, Richtig, Erika, Ziemer, Mirjana, Mangana, Johanna, Terheyden, Patrick, Loquai, Carmen, Nguyen, Van Anh, Gebhardt, Christoffer, Meier, Friedegund, Diem, Stefan, Cozzio, Antonio, Flatz, Lukas, Röcken, Martin, Garbe, Claus, Eigentler, Thomas K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126291/
https://www.ncbi.nlm.nih.gov/pubmed/33986126
http://dx.doi.org/10.1136/jitc-2021-002350

Ejemplares similares

Ejemplares similares